Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
2001 · PubMed · 775 citations
J
Jordi Codony‐Servat
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
111
Papers
3.4K
Citations
27
h-index
38
i10-index
Jordi Codony‐Servat is an academic researcher from Hospital Universitario Dexeus. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Prostate Cancer Treatment and Research & Cancer, Lipids, and Metabolism. The author has an h-index of 27, co-authored 95 publications.
ORCID: 0000-0001-8239-9016Papers by this author
worksCleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells.
1999 · PubMed · 238 citations
Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse
2005 · British Journal of Cancer · 113 citations
https://doi.org/10.1038/sj.bjc.6602851
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
2006 · Molecular Cancer Therapeutics · 106 citations
https://doi.org/10.1158/1535-7163.mct-05-0147
Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)
2018 · EBioMedicine · 44 citations
https://doi.org/10.1016/j.ebiom.2018.11.036
KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)
2023 · Critical Reviews in Oncology/Hematology · 26 citations
https://doi.org/10.1016/j.critrevonc.2023.104228
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat